Diagnostic value of TRACP5b expression in patients with bone tumors

Q. Zhang, L. Cao, XD. Miao, YP. Wu

Article ID: 5408
Vol 33, Issue 2, 2019
DOI: https://doi.org/10.54517/jbrha5408
Received: 4 January 2019; Accepted: 4 January 2019; Available online: 9 May 2019; Issue release: 9 May 2019

Abstract

In order to investigate the diagnostic value of serum levels of tartrate-resistant acid phosphatase 5b (TRACP5b) in patients with bone tumors, enzyme linked immunosorbent assay (ELISA) was used to com¬pare serum levels of TRACP5b and alkaline phosphatase (ALP) in bone tumor patients (experimental group, 80 cases) and healthy controls (control group, 36 cases). It was found that the serum level of TRACP5b in the experimental group was significantly higher than that in the control group. In addition, the sensitivity and specificity of serum TRACP5b were higher than those of serum ALP in the diagnosis of bone tumors. Fur¬thermore, the serum level of TRACP5b was positively correlated with that of ALP. Therefore, it was conclud¬ed that the serum level of TRACP5b may be used as a sensitive indicator of bone tumors, and the sensitivity and specificity of TRACP5b are even higher than those of ALP in the diagnosis of bone tumors.


Keywords

bone tumors;tartrate-resistant acid phosphatase 5b;tumor markers;diagnosis;clinical value


References

Supporting Agencies



Copyright (c) 2019 Q. Zhang, L. Cao, XD. Miao, YP. Wu




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).